Published in
American Association for the Advancement of Science, Science Translational Medicine, 510(11), 2019
DOI: 10.1126/scitranslmed.aaw7999
Links
Tools
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Journal article published in 2019 by
Miriam Molina-Arcas 
,
Christopher Moore ,
Sareena Rana,
Febe van Maldegem ,
Edurne Mugarza ,
Pablo Romero-Clavijo ,
Eleanor Herbert ,
Stuart Horswell ,
Lian-Sheng Li ,
Matthew R. Janes,
David C. Hancock ,
Julian Downward
,
Christopher Moore ,
Sareena Rana,
Febe van Maldegem ,
Edurne Mugarza ,
Pablo Romero-Clavijo ,
Eleanor Herbert ,
Stuart Horswell ,
Lian-Sheng Li ,
Matthew R. Janes,
David C. Hancock ,
Julian Downward
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Combined targeting of KRAS-G12C, mTOR, and IGF1R enhances and extends the response to recently developed KRAS-G12C inhibitors in lung cancer models.